Présidents de session
Radiobiologie: IV. Radiobiologie : Session Invités
- Julie CONSTANZO (Radiobiology for Targeted and Personalised Radiotherapy, Institute of Cancer Research of Montpellier (IRCM), INSERM U1194)
- Marie Dutreix (Institut Curie)
Radiobiologie: IV. Radiobiologie : Communications Orales
- Julie CONSTANZO (Radiobiology for Targeted and Personalised Radiotherapy, Institute of Cancer Research of Montpellier (IRCM), INSERM U1194)
- Marie Dutreix (Institut Curie)
Radiobiologie: IV. Radiobiologie : Discussion et Table ronde
- Julie CONSTANZO (Radiobiology for Targeted and Personalised Radiotherapy, Institute of Cancer Research of Montpellier (IRCM), INSERM U1194)
- Marie Dutreix (Institut Curie)
-
Dr Marie Dutreix (Institut Curie)16/03/2022 08:30Radiobiologie
Most of what we know about the biological effects of radiations comes from studies using external beam radiation. Particularly, the therapeutic efficacies of low linear energy transfer LET radiation (X and γ rays, electrons) and high (LET) particles radiation used in clinic have been extensively investigated. So far, the biological effects of radiation was considered to be strictly dependent...
Go to contribution page -
Dr Jean-Pierre Pouget (IRCM, Montpellier)16/03/2022 09:00Radiobiologie
Radionuclide therapy consists of the selective irradiation of tumour cells deriving from a radiolabelled molecule or device, specifically located at the tumour site. The consequent effect, on both tumours and normal tissues involved, depends not only on the modality of absorbed dose delivery but also on the specific characteristics of the irradiated tissue and of its microenvironment....
Go to contribution page -
Dr Marta Cremonesi (IEO, Milan)16/03/2022 09:30Radiobiologie
In recent years, Targeted Radionuclide Therapy (TRT) is showing exponential increase of applications due to the availability of new receptor directed ligands, metabolic precursors, monoclonal antibodies, and innovative devices - such as microspheres embedded with radionuclides. A variety of radionuclides, emitting nuclear particles with a range of path lengths from nanometres to millimetres,...
Go to contribution page -
Dr Joëlle GASCHET (CRCI2NA, Nantes)16/03/2022 10:00Radiobiologie
Alpha-radiotherapy is an internal radiation therapy based on the use of α-particle emitters. These radionuclides are highly cytotoxic and altogether their characteristics make them of particular interest in the treatment of disseminated cancers, minimal residual disease and micro-metastases. Nowadays there is a growing interest for these α-emitters whose development in the clinic was so far...
Go to contribution page -
AliAsghar PARACH (Radiobiology for Targeted and Personalised Radiotherapy Team Institute of Cancer Research of Montpellier (IRCM – U1194))16/03/2022 10:50Radiobiologie
Introduction.
Go to contribution page
Preclinical studies provide detailed information to evaluate the efficacy and safety of a new radiopharmaceuticals for diagnostic and therapeutic applications. In molecular radiotherapy (MRT) it is essential to calculate absorbed doses to the various structures of interest. Uncertainties in external beam radiotherapy are around 2% to 4%. In contrast, dosimetry for MRT suffers... -
Victor Levrague (LPSC)16/03/2022 11:10Radiobiologie
Abstract en pièce jointe, en format .docx et .pdf (pour plus de facilité de lecture)
Go to contribution page -
Malick BIO IDRISSOU (IRCM)16/03/2022 11:30Radiobiologie
Contexte : Les radionucléides émetteurs d’électrons Auger (EEA) sont très attractifs en thérapie ciblée car ils permettent d’irradier spécifiquement les cellules tumorales ciblées tout en épargnant les tissus sains. Cependant, en raison de leur faible parcours (2 à 500 nm pour énergie < 1KeV) dans les tissus biologiques, il est nécessaire de délivrer les EEA à proximité de cibles...
Go to contribution page -
Mme Laura Ordas (IRCM Montpellier)16/03/2022 11:50Radiobiologie
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer associated with a poor prognosis. Current treatments, such as chemotherapy and radiotherapy, fail to improve patient survival. This failure can be explained by PDAC high desmoplasia where cancer associated fibroblasts (CAFs) are the main contributor. Indeed, after conventional X-rays radiotherapy (X-RT), CAFs adopt a senescent...
Go to contribution page -
Dr Marta Cremonesi (IEO, Milan)
In recent years, Targeted Radionuclide Therapy (TRT) is showing exponential increase of applications due to the availability of new receptor directed ligands, metabolic precursors, monoclonal antibodies, and innovative devices - such as microspheres embedded with radionuclides. A variety of radionuclides, emitting nuclear particles with a range of path lengths from nanometres to millimetres,...
Go to contribution page -
Dr Joëlle Gaschet (CRCI2NA, Nantes)
Alpha-radiotherapy is an internal radiation therapy based on the use of α-particle emitters. These radionuclides are highly cytotoxic and altogether their characteristics make them of particular interest in the treatment of disseminated cancers, minimal residual disease and micro-metastases. Nowadays there is a growing interest for these α-emitters whose development in the clinic was so far...
Go to contribution page -
Dr Marie Dutreix (Institut Curie)
Most of what we know about the biological effects of radiations comes from studies using external beam radiation. Particularly, the therapeutic efficacies of low linear energy transfer LET radiation (X and γ rays, electrons) and high (LET) particles radiation used in clinic have been extensively investigated. So far, the biological effects of radiation was considered to be strictly dependent...
Go to contribution page -
Dr Jean-Pierre Pouget (IRCM, Montpellier)
Radionuclide therapy consists of the selective irradiation of tumour cells deriving from a radiolabelled molecule or device, specifically located at the tumour site. The consequent effect, on both tumours and normal tissues involved, depends not only on the modality of absorbed dose delivery but also on the specific characteristics of the irradiated tissue and of its microenvironment....
Go to contribution page